Medicine and Dentistry
Hypoglycemia
100%
Patient
95%
Glycemic Control
82%
Insulin Detemir
80%
Observational Study
56%
Insulin
46%
Therapeutic Procedure
44%
Maturity Onset Diabetes of the Young
41%
Primary Health Care
39%
Glucose
35%
Hemoglobin A1c
35%
Adverse Drug Reaction
23%
Inpatient
23%
Outpatient
23%
Antidiabetic Agent
23%
Evaluation Study
19%
Specialist Care
19%
Physician
19%
Experience
19%
Diabetes
17%
Incidence
11%
Body Weight
11%
Bile Acid Sequestrant
11%
Exenatide
11%
Dipeptidyl Peptidase-4 Inhibitor
11%
Amylin Derivative
11%
Liraglutide
11%
Glucagon-Like Peptide-1 Agonist
11%
Fear
10%
Psychological Well-Being
10%
Distress Syndrome
10%
Patient Population
9%
Glycated Hemoglobin
9%
Logistic Regression Analysis
9%
Odds Ratio
9%
Adjustment
9%
Research Design
9%
Combination Therapy
7%
Association
7%
Follow up
7%
Add on Therapy
7%
Insulin Treatment
7%
Body Weight Change
7%
Glycon
7%
Introspection
7%
Weight Loss
7%
Oral Antidiabetic Agent
7%
Age
7%
Quality of Life
7%
Nursing and Health Professions
Weight
43%
Obstetric Delivery
39%
Patient Preference
39%
Glucagon Like Peptide 1 Receptor Agonist
37%
Patient
36%
Antidiabetic Agent
36%
Patient with Type 2 Diabetes
36%
Insulin Detemir
31%
Inpatient
28%
Insulin
27%
Drug
26%
Nausea
26%
Experiment
26%
Body Weight
24%
Non Insulin Dependent Diabetes Mellitus
24%
Body Weight Loss
20%
Procedures
16%
Drug Therapy
16%
Glucose Blood Level
15%
Age Groups
13%
Analysis
13%
Control
13%
Drug Administration Route
13%
Urinary Tract Infection
13%
Adverse Event
13%
Devices
13%
Dipeptidyl Peptidase IV Inhibitor
11%
Bile Acid Sequestrant
11%
Liraglutide
11%
Exendin 4
11%
Amylin Derivative
11%
Hypoglycemia
11%
Diabetes Mellitus
7%
Add on Therapy
7%
Metformin
7%
Insulin Treatment
7%
Body Weight Gain
7%
Medical Specialist
7%
Oral Antidiabetic Agent
7%
Combination Therapy
7%
Adverse Drug Reaction
7%
Pharmacology, Toxicology and Pharmaceutical Science
Insulin Detemir
70%
Hypoglycemia
50%
Non Insulin Dependent Diabetes Mellitus
44%
Glucagon Like Peptide 1 Receptor Agonist
37%
Antidiabetic Agent
36%
Glucose
35%
Insulin
27%
Nausea
26%
Drug
26%
Adverse Drug Reaction
23%
Diabetes Mellitus
23%
Hemoglobin A1c
15%
Adverse Event
13%
Urinary Tract Infection
13%
Route of Administration
13%
Incidence
11%
Liraglutide
11%
Bile Acid Sequestrant
11%
Dipeptidyl Peptidase IV Inhibitor
11%
Exendin 4
11%
Amylin Derivative
11%
Oral Antidiabetic Agent
7%
